Found: 16
Select item for more details and to access through your institution.
The International Myeloma Society Comes of Age.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 1, doi. 10.1016/j.clml.2012.01.002
- By:
- Publication type:
- Article
The International Myeloma Society comes of age.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
The Medical Research Council Myeloma IX Trial: New Clinical Insights on the Anticancer Effects of Zoledronic Acid in Patients With Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 2, doi. 10.1016/j.clml.2011.03.025
- By:
- Publication type:
- Article
How to Manage Neutropenia in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 5, doi. 10.1016/j.clml.2011.11.001
- By:
- Publication type:
- Article
Considerations in the Management of Elderly Patients With Chronic Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 12, doi. 10.1016/j.clml.2011.10.001
- By:
- Publication type:
- Article
Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Bortezomib (Velcade), Rituximab, Cyclophosphamide, and Dexamethasone Combination Regimen Is Active as Front-Line Therapy of Low-Grade Non-Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 26, doi. 10.1016/j.clml.2011.05.040
- By:
- Publication type:
- Article
Bortezomib (velcade), rituximab, cyclophosphamide, and dexamethasone combination regiment is active as front-line therapy of low-grade non-Hodgkin lymphoma.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Prognostic Value of Platelet Count in Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 32, doi. 10.1016/j.clml.2011.09.215
- By:
- Publication type:
- Article
Prognostic Risk Factor Evaluation in Patients With Relapsed or Refractory Multiple Myeloma Receiving Lenalidomide Treatment: Analysis of Renal Function by eGFR and of Additional Comorbidities by Comorbidity Appraisal.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 38, doi. 10.1016/j.clml.2011.09.216
- By:
- Publication type:
- Article
Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Silencing of Notch3 Using shRNA driven by survivin promoter inhibits growth and promotes apoptosis of human T-cell acute lymphoblastic leukemia cells.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Risk factors fo Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 70, doi. 10.1016/j.clml.2011.10.002
- By:
- Publication type:
- Article
Rapidly Fatal Acute ATLL Emerging After Methotrexate Therapy for Disseminated Psoriasis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 76, doi. 10.1016/j.clml.2011.02.010
- By:
- Publication type:
- Article